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4Abstract
Background	Micronutrient	deficiencies	including	selenium	(Se)	are	widespread	in
Malawi	and	potentially	underlie	a	substantial	disease	burden,	particularly	among
poorer	and	marginalised	populations.	Concentrations	of	Se	in	staple	cereal	crops
can	be	increased	through	application	of	Se	fertilisers	–	a	process	known	as
agronomic	(agro-)	biofortification	–	and	this	may	contribute	to	alleviating
deficiencies.	The	Addressing	Hidden	Hunger	with	Agronomy	(AHHA)	trial	aims	to
establish	the	efficacy	of	this	approach	for	improving	Se	status	in	rural	Malawi.
Methods	A	double-blind,	randomised,	controlled	trial	will	be	conducted	in	a	rural
community	in	Kasungu	District,	Central	Region,	Malawi.	The	hypothesis	is	that
consumption	of	maize	flour	agro-biofortified	with	Se	will	increase	serum	Se
concentration.	We	will	recruit	180	women	of	reproductive	age	(WRA;	20–45	years)
and	180	school-aged	children	(SAC;	5–10	years)	randomised	in	a	1:1	ratio	to	receive
either	maize	flour	enriched	through	agro-biofortification	with	Se	or	a	control	flour
not	enriched	with	Se.	Households	will	receive	flour	(330	g	capita	-1	day	-1	)	for	12
weeks.	The	primary	outcome	is	Se	concentration	in	serum	(µg	L	-1	).	Serum	will	be
extracted	from	venous	blood	samples	drawn	at	baseline	(prior	to	flour	distribution)
and	end-line.	Selenium	concentration	will	be	measured	using	Inductively	Coupled
Plasma	Mass	Spectrometry	(ICPMS).	Discussion	Findings	will	be	communicated	to
policy	stakeholders	and	participating	communities	and	reported	in	peer-reviewed
journals.	Trial	registration	The	Addressing	Hidden	Hunger	with	Agronomy	(Malawi)
trial	is	registered	(March	2019;	ISCRTN85899451).
Background
5Micronutrient	deficiencies	are	widespread	in	Malawi	[1].	Selenium	is	an	essential
micronutrient	with	important	roles	in	thyroid	function	and	cognitive	development
and	as	a	component	of	selenoprotein	antioxidants	[2,3].	In	a	recent	study	of	a
nationally-representative	sample	of	Malawian	women	and	pre-school	children,
plasma	Se	concentrations	were	below	the	threshold	for	optimal	activity	of	the	anti-
oxidant	enzyme	glutathione	peroxidase	3	(GPx3)	in	62%	of	women	(15-49	years;
n=754)	and	86%	of	pre-school	children	(6-59	months;	n=990)	[4].	Deficiency	of	Se
occurs	due	to	inadequate	dietary	Se	intakes,	and	this	is	driven	by	low
concentrations	of	plant-available	Se	in	the	weathered	agricultural	soils	that	are
typical	of	Malawi	[5,	6,	7].
There	are	various	potential	strategies	to	alleviate	Se	deficiencies	including	dietary
diversification,	food	fortification	at	processing	stage	and	supplementation.
Alternatively,	the	concentration	of	bioavailable	Se	can	be	increased	in	the	edible
portion	of	staple	crops	–	a	process	known	as	biofortification.	For	some
micronutrients,	biofortification	can	be	achieved	through	crop	breeding	[8],	but	agro-
biofortification	(i.e.	application	of	micronutrient	fertilisers)	is	required	for	Se	due	to
the	dominance	of	environmental	over	genetic	controls	of	Se	concentration	in	crops
[9].	Agro-biofortification	of	maize	can	increase	concentrations	of	Se	in	the	grain	and
may	be	a	cost-effective	and	equitable	strategy	in	Malawi	where	maize	contributes
60%	of	dietary	energy	supply,	and	more	among	poorer	populations	[5,	7].
Agro-biofortification	with	Se	has	policy	precedent	in	Finland	where	incorporation	of
Se	into	granular	fertilisers	has	been	mandatory	since	1984.	Mean	plasma	Se
concentrations	of	adults	(n=60)	increased	from	70.3	μg	L-1	prior	to	the	fertiliser
policy	change	to	110.5	μg	L-1	in	2010	which	is	considered	optimal	status	[10].
6However,	this	strategy	has	not	been	implemented	in	low-middle	income	countries
where	agriculture,	food	systems	and	dietary	patterns	are	substantially	different
from	those	in	high-income	countries.
This	study	aims	to	test	the	efficacy	of	improving	Se	status	among	a	rural	Malawian
population	through	consumption	of	maize	flour	enriched	with	Se	through	agro-
biofortification.	The	evidence	may	inform	fertiliser	policies	in	Malawi.
Method	and	Design
Study	setting
The	Addressing	Hidden	Hunger	with	Agronomy	(AHHA)	Malawi	trial	will	be	conducted
in	Wimbe	Traditional	Authority	(TA),	Kasungu	District,	Central	Region,	Malawi.	The
study	area	was	selected	due	to	the	high	prevalence	of	Se	deficiency	[4].	Most
households	rely	on	subsistence	farming	alongside	smallholder	and	estate	tobacco
production	[11].	To	define	a	study	area,	two	neighbouring	Enumeration	Areas	(EAs)
were	randomly	selected	from	a	total	of	51	EAs	in	Wimbe	TA;	EAs	are	the	primary
sampling	unit	of	the	national	Demographic	and	Health	Survey	(DHS).	We	conducted
a	census	to	create	a	list	of	all	households	in	the	EA	(n=1179)	and	a	roster	of	all
household	members.
Study	design
The	AHHA	Malawi	trial	is	a	two-arm	randomised,	double-blind,	controlled	trial	with
participants	receiving	maize	flour	enriched	through	agro-biofortification	with	Se	or	a
control	flour	that	is	not	enriched	with	Se	(Figure	1).
	
Prior	to	baseline	assessments,	180	households	will	be	randomly	selected	from
eligible	households	(see	inclusion	criteria).	An	additional	50	households	will	be	pre-
7selected	in	case	of	consent	refusals.	Households	will	be	visited	for	recruitment	of
one	non-pregnant	woman	of	reproductive	age	(WRA;	20-45	years)	and	one	school-
aged	child	(SAC;	5-10	years).	Recruitment	and	baseline	questionnaires	will	be
conducted	in	the	household	and	participants	subsequently	directed	to	nearby
mobile	field	clinics	set	up	in	large	tents	where	anthropometry	and	blood	sampling
will	be	conducted.	Recruitment	will	be	conducted	by	trained	Research	Assistants
(RAs)	hired	by	Lilongwe	University	of	Agriculture	and	Natural	Resources	(LUANAR).
The	trial	aims	to	recruit	180	WRA	and	180	SAC.
After	baseline,	households	will	be	randomly	allocated	in	a	1:1	ratio	to	receive	Se
flour	(n=90)	or	control	flour	(n=90).	The	trial	statistician	will	allocate	households
remotely	using	a	computer-based	randomisation	programme.	Intervention	allocation
will	be	concealed	from	participants,	RAs	conducting	the	baseline	and	end-line
surveys,	laboratory	analysts	and	those	involved	in	managing	or	over-seeing	the
trial.	Locally,	only	the	supervisor	of	the	maize	flour	distribution	will	know	the
allocation	of	households	to	treatments.
Inclusion	criteria
Household	level:
Household	members	include	at	least	one	non-pregnant	WRA	(aged	20-45	years)	and	at	least	one
SAC	(aged	5-10	years)	in	residence	during	July-October.
Household	typically	prepares	and	consumes	meals	at	home.
Household	head	agrees	that	the	household	will	receive	and	all	members	consume	maize	flour	in
place	of	their	own	flour	for	the	12-week	flour	distribution	period.
Individual	level:
One	non-pregnant	WRA	(aged	20-45	years)	and	one	SAC	(aged	5-10	years)	per	household.
Pregnancy	status	is	self-reported.
Participant	is	planning	to	be	in	residence	in	the	household	during	July-October.
Participant	WRA	is	willing	and	able	to	provide	consent,	and	the	caretaker	of	the	participant	SAC
is	willing	and	able	to	provide	assent.
Formative	work
8The	trial	delivery	team	have	undertaken	substantial	preparatory	work	with	the
community.	Formative	work	was	conducted	in	July–September	2018	to	identify
potential	concerns	among	community	members	about	participation	in	the	trial	and
to	develop	mitigating	strategies.	Community	engagement	activities	have	been
conducted	subsequently	including	briefings	with	traditional	leaders	and	relevant
government	officials,	question	and	answer	sessions	with	each	village	in	the	study
area,	and	a	community	visit	to	the	maize	production	site.
Description	of	treatment
The	flour	distribution	period	will	last	12	weeks	during	July–October	2019.	The
intervention	will	begin	1–2	weeks	after	baseline	assessment	is	complete.	End-line
blood	samples	will	be	taken	1–2	weeks	prior	to	the	final	flour	distribution	(Figure	2).
Maize	flour	will	be	distributed	to	intervention	and	control	households	in	multiples	of
5	and	10	kg	sacks	at	pre-determined	distribution	points	set	up	in	vicinity	to	villages.
Households	will	receive	sufficient	maize	flour	to	meet	requirements	for	the	12-week
flour	distribution	period	with	distributions	at	six	timepoints.	Household
requirements	will	be	calculated	based	on	estimated	consumption	of	330	g	capita-1
day-1	for	all	household	members	over	the	age	of	1	year	(equivalent	to	10	kg	capita-1
month-1).
The	provision	of	non-biofortified	flour	to	control	households	allows	the	trial	to	be
blinded.	However,	bags	of	maize	flour	will	be	labelled	to	ensure	households	receive
the	correct	treatment,	and	for	monitoring	of	consumption.	The	trial	statistician	will
generate	a	set	of	unique	seven-digit	codes	that	will	be	used	to	label	the	bags	of
study	flour.	The	statistician	will	communicate	the	treatment	codes	directly	to	the
maize	flour	distribution	team	lead.	Only	the	trial	statistician	and	maize	distribution
9team	will	know	how	to	interpret	the	code.	The	rest	of	the	trial	team	and	participants
will	be	blinded	to	treatment	allocation.	At	distribution	points,	study	flour	bags	will
be	stacked	in	piles	according	to	the	bag	code.	Participants	will	present	their	ID
cards	(Appendix	2i)	and	the	maize	distribution	team	will	check	their	allocated
treatment	before	providing	the	correct	quantity	and	type	of	flour.	Participants	will
receive	help	transporting	maize	flour	to	their	home	if	necessary.
Non-participating	households	in	the	study	area	will	also	receive	non-biofortified
flour	for	the	duration	of	the	study.	Control-equivalent	flour	will	not	be	labelled	with
codes	and	will	be	distributed	separately.	The	provision	of	free	flour	to	non-
participant	households	was	deemed	appropriate	to	avoid	individuals	feeling	coerced
into	participating	in	the	trial,	to	avoid	jealousy	or	stigma	within	the	community,	and
to	reduce	the	likelihood	of	sharing	flour	between	households.
The	trial	maize	was	grown	at	LUANAR,	Bunda	Campus,	Malawi.	A	widely	grown
hybrid	cultivar	(DKC80-53)	was	grown	using	conventional	agronomy.	Plants	were
spaced	at	0.25	m	within-rows;	the	distance	between	rows	was	0.75	m.	When	the
crop	was	approximately	1-1.5	m	in	height,	at	the	pre-tasselling	stage,	sodium
selenate	solution	was	sprayed	continuously	along	the	tops	of	ridges	(stem	bases)	at
18	g	Se	ha-1	(elemental	basis)	applied	using	knapsack	sprayers	and	an	application
volume	of	100	L	water	ha-1	[12].	Maize	grain	was	sampled	when	the	crop	was
mature,	approximately	one	month	prior	to	harvest,	and	analysed	by	Inductively
Coupled	Plasma	Mass	Spectrometry	(ICPMS).	At	harvest,	the	mean	concentration	of
Se	was	0.010	mg	kg-1	in	control	grain	and	0.279	mg	kg-1	in	Se-biofortified	grain.	The
Se-biofortified	grain	will	be	blended	in	a	ratio	2:1	with	control	grain	to	obtain	a
concentration	of	0.2	mg	kg-1,	the	target	for	the	intervention	flour.	In	comparison,
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the	median	Se	concentration	in	maize	grain	samples	from	farmer	fields	on	non-
calcareous	soil	types	in	Malawi	was	0.015	mg	kg-1	(n=105)	[5,	7,13].	Grain	will	be
milled	and	packed	in	labelled	sacks.	Milling	equipment	will	be	thoroughly	cleaned
between	processing	the	Se-biofortified	and	control	grain.
Maize	flour	in	Malawi	comes	in	three	main	types:	ufa	mgaiwa	(unrefined),	ufa
granmill	(partly	refined	with	bran	removed	only)	or	ufa	woyera	(fully	refined	with
bran	and	endosperm	removed).	We	will	provide	ufa	granmill	during	the	trial	as	this
was	the	preferred	type	of	flour	among	participants	in	formative	research.
Objectives
The	objective	of	the	study	is	to	test	whether	Se	status	of	non-pregnant	WRA	and
SAC	can	be	improved	through	consumption	of	maize	flour	enriched	with	Se	through
agro-biofortification.	We	hypothesise	that	dietary	Se	intake	will	be	substantially
greater	among	those	receiving	Se-biofortified	maize	flour	compared	to	control	flour,
and	that	this	will	translate	into	increased	Se	status	among	those	receiving	fortified
maize	measured	as	serum	Se	concentration.
Initially,	the	trial	was	designed	to	test	the	efficacy	of	alleviating	Se	and	zinc	(Zn)
deficiency	(May	2019;	ISRCTN85899451).	However,	in	production	of	the	maize	for
the	study,	the	target	maize	Zn	concentration	was	not	reached,	likely	due	to	a
combination	of	soil	factors	and	heavy	rainfall	during	the	2018/19	production	season.
The	planned	Zn	arm	of	the	trial	was	therefore	underpowered	and	dropped	for	ethical
reasons.
Outcome	measures
Primary	outcome	measure
Serum	Se	concentration
Serum	Se	concentrations	will	be	measured	at	baseline	and	end-line.	Whole	venous
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blood	will	be	drawn	into	trace	element–free	tubes	(BD	Diagnostics,	Switzerland)	and
after	clotting	the	serum	will	be	separated	by	centrifugation	within	40	min.	Serum
0.5	mL	aliquots	will	be	transferred	into	cryovials,	transported	in	mobile	freezers	and
stored	at	−80°C.	Serum	samples	will	be	shipped	on	dry	ice	to	the	University	of
Nottingham,	UK,	for	determination	of	elemental	Se	concentration	by	ICPMS	[4].	The
unit	of	measure	is	concentration	of	Se	in	serum	(µg	L-1).
Secondary	outcomes
The	prevalence	of	Se	deficiency	will	be	compared	between	treatment	groups.
Deficiency	will	be	defined	using	established	thresholds	for	the	optimal	activity	of
GPx3	(<84.9 µg L−1),	iodothyronine	deiodinase	(IDI;	<64.8 µg L−1),	and	for	Keshan
Disease	(<30 µg L−1)	which	is	a	cardiomyopathy	linked	to	Se	status	reported	in
China	[14].
Concentration	in	serum	of	the	markers	of	inflammation	alpha	(1)-acid	glycoprotein
(AGP;	mg	L-1)	and	C-reactive	protein	(CRP;	mg	L-1).	These	will	be	measured	using	a
sandwich	ELISA.
Concentration	of	haemoglobin	in	whole	venous	blood	(g	dL-1).	Haemoglobin
concentration	will	be	measured	in	the	field	by	trained	nurses	using	a	portable
HemoCue	Hb201+	(HemoCue	AB,	Ängelholm,	Sweden).
Prevalence	of	anaemia	will	be	compared	between	treatment	groups.	Anaemia	will	be
defined	using	standard	thresholds	[15].
Dietary	Se	intakes	will	be	quantified	among	WRA.	Dietary	data	will	be	collected
among	participating	WRA	using	4-pass	interactive	24-hour	recall.	Two	days	before
the	24-hour	recall,	participants	will	be	given	plates/bowls	and	asked	to	consume
foods	on	a	plate	separate	from	other	family	members.	In	the	first	pass,	participants
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will	be	asked	to	recall	all	foods	and	beverages	they	consumed	over	the	previous	day
(from	midnight	to	midnight).	In	the	second	pass	they	will	be	asked	details	about	the
foods/beverages	and	time/place	of	consumption.	In	the	third	pass,	they	will	be
asked	to	estimate	the	quantity	of	each	food/beverage	consumed	using	an
interviewer-assisted	method	(e.g.,	food	models	and	diet	scales)	and	the	source	of
each	food	(i.e.,	home	produced,	purchased,	the	AHHA	project,	from
neighbours/relatives,	gifted,	food	aid/food	for	work	or	wild).	In	the	fourth	pass,	the
recalled	intake	over	the	day	will	be	reviewed.	Dietary	data	will	be	collected	across
all	days	of	the	week	(population	level)	to	account	for	any	day	of	the	week	effect.	A
repeat	24-hour	recall	will	be	collected	from	a	sub-sample	of	participants	(n=60)	at
least	2	days	after	the	initial	recall.	Dietary	data	will	be	combined	with	relevant	food
composition	data	[7]	to	determine	the	baseline	intakes	of	energy	and
micronutrients.	The	percentage	of	women	at	risk	of	inadequate	intakes	of	Se	will	be
estimated	using	the	Estimated	Average	Requirement	(EAR)	cut-point	method	[16]
after	adjustment	for	intra-subject	variability.	The	percentage	of	energy	from	food
groups,	sub-groups	and	specific	foods	will	be	estimated	to	examine	changes	in	diet
patterns.
Morbidity	outcomes	will	be	self-reported	at	baseline	and	end-line	using	standard
questions	from	the	Malawi	Demographic	and	Health	Survey	(DHS).	Diarrhoea
incidence,	severity	and	duration,	incidence	of	vomiting	and	incidence	of	fever	will
be	recorded	for	WRA	and	SAC.	Prevalence	of	pneumonia	will	be	self-reported	among
SAC	only	(as	per	the	DHS),	i.e.	number	of	days	of	coughing	and	fast	or	difficult
breathing	(due	to	a	problem	in	the	chest)	in	the	two	weeks	prior	to	the	survey.	
Monitoring	of	adherence
Participant	consumption	of	flour	will	be	monitored	during	the	course	of	the
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intervention.	Households	will	be	visited	once	every	15	days.	Research	Assistants	will
observe	the	number	of	10	kg	bags	of	study	flour	that	have	not	been	consumed	and
will	count	and	collect	the	number	of	empty	bags	of	study	flour	for	reconciliation.	A
household	member	responsible	for	meal	preparation	will	be	asked	what	flour	was
used	the	previous	day	for	each	meal;	and	what	quantity	of	non-study	flour	was	used
by	the	household	over	the	past	two	weeks.	The	same	member	of	the	household	will
be	asked	how	many	bags	of	study	flour	have	been	sold	or	gifted	away.	Combined,
these	data	will	provide	a	proxy	measure	of	household	consumption.	Data	collected
for	the	monitoring	of	adherence	will	not	be	used	to	alter	the	amount	of	study	flour
received	by	participating	households	at	future	distribution	time	points.
Monitoring	of	participant	safety
Consumption	of	330	g	capita-1	day -1	of	the	agro-biofortified	maize	flour	with	Se
concentration	of	~0.3	mg	kg-1	would	supply	99	µg	Se	capita-1	day -1.	The	adult
Recommended	Dietary	Allowance	for	Se	is	55	µg	capita-1	day -1	and	the	Tolerable
Upper	Level	of	intake	is	400	µg	day-1	[17].The	concentration	of	Se	in	maize	grain
depends	largely	on	soil	factors,	and	the	concentration	in	Se-biofortified	grain	(mean
0.279	mg	kg-1)	produced	for	this	study	is	within	the	“natural”	range	of	maize	grain
Se	concentrations	observed	previously	in	Malawi	(0.005–0.533	mg	kg-1)	[5].
Comparatively	greater	Se	concentrations	occur	naturally	(i.e.	without	addition	of	Se
fertiliser)	in	maize	grown	on	Eutric	Vertisol	soil	types,	found	in	southern	Malawi	in
the	Shire	Valley	and	along	the	shore	of	Lake	Malawi.
Consumption	of	Se-biofortified	flour	in	the	quantities	provided	in	this	study	is	not
known	or	expected	to	cause	adverse	events.	Procedures	will	be	set	up	to	capture
and	monitor	safety.	Non-serious	Adverse	Events	(AEs)	will	be	captured	and	recorded
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in	electronic	monitoring	forms	by	RAs	during	adherence	monitoring	visits	to
participating	households	(every	15	days).	Research	Assistants	will	ask	participants
and	caregivers	of	children	about	any	AEs	including	fever,	diarrhoea	and	coughing.
These	will	be	compiled	and	reported	to	the	PI	on	a	monthly	basis.
Serious	Adverse	Events	(SAEs)	include	death,	life-threatening	illness,
hospitalisation,	persistent	or	significant	disability,	or	other	such	occurrences,	and
these	will	be	reported	to	the	study	coordination	centre	(LUANAR)	through
completion	of	an	SAE	form	and	submission	within	24	hours	of	the	monitoring	team
being	made	aware	of	the	event.	Participants	will	be	informed	how	to	contact	the
study	coordination	centre;	and	RAs,	Health	Surveillance	Assistants	and	Health
Volunteers	will	be	trained	on	how	to	record	and	report	SAEs.	A	Medical	Doctor	will
be	“on	call”	and	available	to	visit	participants	through	the	duration	of	the
intervention	to	advise	on	seriousness	and	causality.	The	study	principal	investigator
(PI,	Edward	Joy)	will	record	the	event	and	its	seriousness,	causality	and
expectedness.
The	PI	will	report	SAEs	to	the	trial	statistician	who	is	aware	of	random	treatment
allocation,	and	who	will	report	to	the	independent	statistician	on	the	TSC	to	decide
about	the	continuation	of	the	trial.	All	AEs	and	SAEs	will	be	compiled	by	the	PI	and
reported	to	the	Research	Ethics	Committees	(REC)	according	to	their	criteria.
Unblinding	will	only	occur	at	the	request	of	the	independent	statistician	on	the	TSC.
Unblinding	would	involve	revealing	the	allocation	of	households	to	treatment,	e.g.
to	investigate	the	occurrence	of	SAEs	and	their	association	with	treatment.	At	this
point	the	TSC	may	request	the	trial	is	paused	or	terminated.
Withdrawal
Any	individual	will	remain	free	to	withdraw	at	any	time	from	the	study.	If	a
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participant	withdraws	consent	from	further	trial	participation	their	data	will	remain
on	file	and	will	be	included	in	the	final	study	analysis.	If	a	participant	withdraws
consent	for	their	data	to	be	used,	the	data	will	be	destroyed	immediately.
Loss	to	follow	up
Households	or	individuals	that	move	out	of	the	village	will	leave	the	trial	and	no
attempt	will	be	made	to	follow	them	up.	Any	data	collected	from	participants	who
are	lost	to	follow	up	will	be	included	in	the	analysis	where	possible.	Continued
community	engagement	will	be	conducted	to	minimise	loss	to	follow	up.	Contact
details	including	mobile	phone	numbers	have	been	recorded	during	household
enumeration,	and	participants	will	be	contacted	1–2	days	prior	to	the	mobile	clinic
is	set	up	in	their	vicinity.	Mobile	clinics	will	be	located	close	to	participant
households,	and	transport	will	be	provided	if	participants	require.	Also,	participants
will	be	contacted	1–2	days	prior	to	flour	distribution.
Data	collection	and	management
All	participants	will	be	assigned	a	unique	numeric	ID	that	will	be	used	in	data
capture	forms	and	subsequent	analyses	to	maintain	anonymity.	Questionnaire,
anthropometry	and	adherence	data	will	be	collected	by	trained	RAs	in	the	field	via
passcode-protected	tablets	using	Open	Data	Kit	(ODK)	[18].	Blood	samples	will	be
taken	by	trained	and	experienced	nurses	and	processed	to	serum	by	trained
technicians.	Sample	tubes	and	subsequent	data	will	be	labelled	with	unique,
anonymous	codes.	Samples	will	be	logged	in	the	field	using	ODK	forms.	Completed
forms	will	be	uploaded	to	a	secure	cloud	server	daily	and	will	be	encrypted	for
security.	Mobile	clinic	team	leads	will	report	daily	to	the	anthropometry	and	blood
collection	team	supervisors	to	ensure	standard	procedures	are	followed.	The	Trial
Manager	and	Data	Manager	will	reconcile	samples	and	data	forms	daily.
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Recruitment	rates	and	number	of	eligible	individuals	will	be	assessed	and	compared
with	numbers	enrolled,	and	completeness	of	follow-up.
Dietary	data	will	be	collected	by	trained	RAs,	using	a	paper-based	data	collection
process.	Dietary	forms	will	be	labelled	with	participant	IDs.	Data	collection	will	be
supervised	by	the	diet	team	supervisor	who	will	observe	individual	24-hour	recalls
and	check	the	data	collected	each	day.	The	RA,	supervisor	and	co-ordinator	will	sign
off	all	forms	before	they	are	filed	for	data	entry.	Quality	control	check	lists	(for
observations	and	forms)	will	be	used	to	ensure	standard	procedures	are	followed.	At
the	end	of	the	baseline	and	end-line	surveys,	all	diet	data	will	be	double	entered	to
reduce	errors	and	ensure	consistent	data	entry	decisions	are	made.
The	Data	Manager	will	hold	the	data	tables	that	match	participant	ID	to	sample
codes,	and	these	will	not	be	available	to	the	Trial	Statistician	until	after	statistical
analyses	are	complete.	Thus,	the	trial	statistician	will	be	blinded	to	treatments.
Sample	analysis	will	be	undertaken	by	Malawian	and	UK	study	collaborators	in
laboratories	in	the	UK.	Good	practices	in	quality	control	will	be	followed	such	as
analysis	in	duplicate	and	inclusion	of	sample	blanks	and	reference	materials	and
use	of	sufficiently	sensitive	analytical	instrumentation	to	ensure	quantification	of
the	variables	of	interest.
All	data	collection	and	storage	will	be	compliant	with	the	General	Data	Protection
Regulation	[19]	and	the	conditions	of	the	REC	Approval.	Anonymised	data	will	be
uploaded	to	an	open	data	platform	following	analysis	in	compliance	with	open
access	data	requirements.	Data	will	be	kept	for	a	minimum	of	10	years	after
completion	of	the	trial.
Biological	sample	management
Serum	samples	will	be	transported	in	cool	boxes	packed	with	ice	from	mobile	field
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clinics	to	the	Community	Health	Surveillance	Unit,	Ministry	of	Health,	Area	3,
Lilongwe,	where	they	will	be	stored	at	-80°C.	Cryovials	and	cryovial	racks	will	be
labelled	with	unique	numeric	and	QR	codes.	Instrumentation	and	methodologies	are
not	established	in	Malawi	for	ICPMS	to	measure	elemental	concentrations	in	the
parts-per-billion	range.	Samples	will	be	transferred	on	dry	ice	to	a	secure	laboratory
at	the	University	of	Nottingham,	UK	under	a	Material	Transfer	Agreement	(MTA)	with
appropriate	licences.	Samples	will	be	cross-checked	with	shipment	lists.	Following
ICPMS	analysis,	samples	will	be	stored	for	a	period	of	5	years	following	completion
of	the	trial	after	which	they	will	be	destroyed	in	accordance	with	licence	and	safety
requirements.
Statistical	analysis
The	trial	is	designed	to	have	statistical	power	to	detect	an	increase	in	Se
concentration	in	serum	of	4.9	µg	L-1	with	5%	significance	and	90%	power,	allowing
for	20%	drop-out,	based	on	a	standard	deviation	of	9.0	µg	Se	L-1	(standardised
difference	of	0.54).	In	a	recent	national	survey,	the	mean	plasma	Se	concentration
among	adult	women	in	Malawi	was	83.7	µg	L-1	[4]	and	the	trial	is	powered	to
increase	Se	concentration	above	the	threshold	for	optimal	activity	of	GPx3	(<84.9 
µg L−1).
Data	on	the	number	of	participants	(WRA	and	SAC)	randomised	(with	exclusions	and
reasons	for	exclusion),	the	flow	of	participants	through	enrolment,	allocation	to
intervention,	follow-up	and	analysis	will	be	presented	in	a	flow	chart.
The	primary	analysis	will	be	carried	out	on	groups	as	randomised	(‘intention	to
treat’).
Tabulation	of	demographic	data	and	other	characteristics	will	be	done	using	the
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intention-to-treat	datasets.	No	significance	tests	will	be	performed	to	test	for
differences	at	baseline.	Descriptive	statistics	for	continuous	variables	will	include
the	mean,	standard	deviation,	median,	range	and	the	number	of	observations.
Categorical	variables	will	be	presented	as	numbers	and	percentages.
For	the	primary	outcome,	analysis	of	covariance	(adjusting	for	baseline	values)	will
be	used	to	estimate	a	mean	difference	in	Se	status	between	the	two	arms	of	the
trial.	The	results	will	be	presented	with	a	95%	confidence	interval.	For	secondary
outcomes,	appropriate	models	will	be	used	to	examine	the	effect	of	the	relevant
intervention.	Appropriate	measures	of	effects	will	be	reported	with	95%	confidence
intervals.
Unadjusted	and	adjusted	results	will	be	presented	for	all	analyses.	Planned
subgroup	analyses	for	WRA	will	include	10-year	age	groups	(20-29,	30-39,	40-45
years),	lactation	status	(yes	–	exclusive	breastfeeding;	yes	–	breastfeeding	and
complementary	feeding;	no),	and	pregnancy	status	(self-reported	at	end-line).	All
sub-group	analyses	will	be	performed	by	including	a	variable	(or	variables,	as
appropriate)	for	the	sub-group	and	its	interaction	with	the	treatment	in	the	model.
Results	will	be	interpreted	with	due	caution.	Full	details	of	all	analyses,	including
any	additional	covariates	to	be	included	in	the	adjusted	models,	will	be	set	out	a
priori	in	a	Statistical	Analysis	Plan.
Whilst	we	have	allowed	for	20%	missing	data	in	the	sample	size	calculations,	only	a
small	amount	of	missing	data	is	expected	and	it	is	unlikely	that	it	will	have	to	be
accounted	for	in	any	analysis.	We	would	consider	using	multiple	imputation	if
missing	data	were	larger	than	expected	and/or	there	was	differential	attrition
between	the	trial	arms.	We	would	also	attempt	to	ensure	that	the	reason	for	the
differential	attrition	was	fully	understood.
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Discussion
The	AHHA	Malawi	trial	is	a	pragmatic,	community-based	trial	that	will	provide
evidence	on	the	efficacy	of	alleviating	Se	deficiency	through	consumption	of	maize
flour	enriched	with	Se	through	agro-biofortification.	Agro-biofortification	may	be	a
cost-effective	way	to	alleviate	Se	deficiency	in	Malawi,	with	previous	studies
estimating	a	cost-per-alleviated	case	of	~ US$	0.36	year−1	[7].	The	evidence	from
the	trial	may	be	used	to	inform	future	agriculture	policy	in	Malawi	and	the	wider
region.	The	trial	findings	will	be	communicated	to	policy	stakeholders	and
participating	communities,	and	reported	in	peer-reviewed	journals.
Trial	Status
Protocol	version	4.2
Recruitment	started	on	26th	June	and	was	completed	on	6th	July	2019.
Abbreviations
AE																											Adverse	Event
AGP																							Alpha	(1)-acid	glycoprotein
AHHA																				Addressing	Hidden	Hunger	with	Agronomy
CRP																								C-reactive	protein
DHS																								Demographic	and	Health	Survey
EA																											Enumeration	Area
EAR																								Estimated	Average	Requirement
GPx3																					Glutathione	Peroxidase	3
ICPMS																			Inductively	Coupled	Plasma	Mass	Spectrometry
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ID																												Identifier
LUANAR															Lilongwe	University	of	Agriculture	and	Natural	Resources
ODK																							Open	Data	Kit
MTA																						Material	Transfer	Agreement
PI																												Principal	Investigator
RA																										Research	Assistant
REC																								Research	Ethics	Committee
SAC																								School-Aged	Children
SAE																								Serious	Adverse	Event
Se																											Selenium
TA																											Traditional	Authority
TSC																									Trial	Steering	Committee
UK																										United	Kingdom
WRA																						Women	of	Reproductive	Age
Zn																											Zinc
Declarations
Ethics	approval	and	consent	to	participate
The	trial	is	being	conducted	in	accordance	with	the	principles	of	Good	Clinical
Practice	[20].	Ethical	approval	for	the	formative	research	was	sought	and	obtained
from	the	London	School	of	Hygiene	&	Tropical	Medicine	Observational	Research
Ethics	Committee	(reference:	15730)	and	the	Malawi	College	of	Medicine	Research
Ethics	Committee	(reference:	P.05/18/2393).		The	trial	protocol	and	amendments
have	been	approved	by	the	London	School	of	Hygiene	&	Tropical	Medicine
Interventions	Research	Ethics	Committee	(reference:	16181)	and	the	Malawi	College
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of	Medicine	Research	Ethics	Committee	(reference:	P.11/18/2539)	and	is	a
registered	clinical	trial	(March	2019;	ISCRTN85899451).
Participation	in	the	study	is	voluntary.	Trained	RAs	will	seek	written	informed
consent	for	WRA	and	assent	for	SAC	in	the	presence	of	an	adult	caregiver	prior	to
recruitment.	Participants	have	the	right	to	withdraw	at	any	stage.
Trial	Steering	Committee
The	AHHA	Malawi	trial	is	overseen	by	a	Trial	Steering	Committee	(TSC),	with	the
following	independent	members:	Professor	Penelope	Nestel	(chair),	Dr	Chrissie
Thakwalakwa	(Malawi	nutrition	expert)	and	Dr	Charles	Opondo	(statistician).	The
TSC	is	responsible	for	overseeing	the	safe	and	ethical	conduct	of	the	trial	according
to	the	standards	set	out	in	the	ICH	Guidelines	for	Good	Clinical	Practice.	The	AHHA
study	is	considered	a	low-risk	trial	due	to	the	nature	of	the	intervention.
Furthermore,	no	interim	data	will	be	collected.	Thus,	there	will	not	be	a	Data
Monitoring	Committee;	instead,	the	independent	statistician	will	advise	on	the
continuation/discontinuation	of	the	trial	following	safety	reports	from	the	PI.
The	Trial	Management	Group	will	discuss	any	potential	protocol	amendments	with
the	TSC.	If	the	TSC	approves	the	amendment,	then	an	application	will	be	submitted
to	the	RECs.	Participant	Information	Sheets	will	be	updated	accordingly.
Consent	for	publication
Not	applicable
Availability	of	data	and	material
Data	sharing	is	not	applicable	to	this	article	as	no	datasets	were	generated	or
analysed	during	the	current	study.
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Figures
Figure	1
CONSORT	diagram	of	the	Addressing	Hidden	Hunger	with	Agronomy	(AHHA)	Malawi	trial.	The	trial	aims	to	recruit	180	school-aged	children	(SAC)	and	180	women	of	reproductive	age	(WRA).
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Figure	2
Schedule	of	enrolment,	interventions,	and	assessments	for	the	Addressing	Hidden	Hunger	with	Agronomy	Malawi	trial.
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